HRP20171896T1 - Liječenje i prevencija alzheimerove bolesti - Google Patents
Liječenje i prevencija alzheimerove bolesti Download PDFInfo
- Publication number
- HRP20171896T1 HRP20171896T1 HRP20171896TT HRP20171896T HRP20171896T1 HR P20171896 T1 HRP20171896 T1 HR P20171896T1 HR P20171896T T HRP20171896T T HR P20171896TT HR P20171896 T HRP20171896 T HR P20171896T HR P20171896 T1 HRP20171896 T1 HR P20171896T1
- Authority
- HR
- Croatia
- Prior art keywords
- aluminum oxyhydroxide
- use according
- patient
- aluminum
- oxyhydroxide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166355 | 2014-04-29 | ||
| EP14166354 | 2014-04-29 | ||
| EP15720059.3A EP3137093B1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
| PCT/EP2015/059339 WO2015165966A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171896T1 true HRP20171896T1 (hr) | 2018-02-23 |
Family
ID=53039896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171896TT HRP20171896T1 (hr) | 2014-04-29 | 2015-04-29 | Liječenje i prevencija alzheimerove bolesti |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10478454B2 (enExample) |
| EP (2) | EP3269376B1 (enExample) |
| JP (1) | JP6692755B2 (enExample) |
| KR (1) | KR102388363B1 (enExample) |
| CN (1) | CN106659738B (enExample) |
| AU (1) | AU2015254663B2 (enExample) |
| CA (1) | CA2946928C (enExample) |
| CY (1) | CY1119674T1 (enExample) |
| DK (1) | DK3137093T3 (enExample) |
| ES (2) | ES2824763T3 (enExample) |
| HR (1) | HRP20171896T1 (enExample) |
| HU (1) | HUE037501T2 (enExample) |
| LT (1) | LT3137093T (enExample) |
| NO (1) | NO3137093T3 (enExample) |
| PL (1) | PL3137093T3 (enExample) |
| PT (1) | PT3137093T (enExample) |
| SI (1) | SI3137093T1 (enExample) |
| WO (1) | WO2015165966A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106535924A (zh) | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) * | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| EP1007040B1 (en) * | 1997-08-21 | 2002-05-08 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment of alzheimer's disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| CN104436212A (zh) * | 2010-03-29 | 2015-03-25 | 诺华股份有限公司 | 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 |
| CN106535924A (zh) * | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
-
2015
- 2015-04-29 WO PCT/EP2015/059339 patent/WO2015165966A1/en not_active Ceased
- 2015-04-29 PT PT157200593T patent/PT3137093T/pt unknown
- 2015-04-29 AU AU2015254663A patent/AU2015254663B2/en active Active
- 2015-04-29 DK DK15720059.3T patent/DK3137093T3/en active
- 2015-04-29 HU HUE15720059A patent/HUE037501T2/hu unknown
- 2015-04-29 US US15/307,082 patent/US10478454B2/en active Active
- 2015-04-29 SI SI201530145T patent/SI3137093T1/en unknown
- 2015-04-29 ES ES17189527T patent/ES2824763T3/es active Active
- 2015-04-29 EP EP17189527.9A patent/EP3269376B1/en active Active
- 2015-04-29 LT LTEP15720059.3T patent/LT3137093T/lt unknown
- 2015-04-29 ES ES15720059.3T patent/ES2651537T3/es active Active
- 2015-04-29 CA CA2946928A patent/CA2946928C/en active Active
- 2015-04-29 NO NO15720059A patent/NO3137093T3/no unknown
- 2015-04-29 EP EP15720059.3A patent/EP3137093B1/en active Active
- 2015-04-29 KR KR1020167033332A patent/KR102388363B1/ko active Active
- 2015-04-29 JP JP2016565267A patent/JP6692755B2/ja active Active
- 2015-04-29 CN CN201580029861.5A patent/CN106659738B/zh active Active
- 2015-04-29 HR HRP20171896TT patent/HRP20171896T1/hr unknown
- 2015-04-29 PL PL15720059T patent/PL3137093T3/pl unknown
-
2017
- 2017-12-13 CY CY20171101303T patent/CY1119674T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3269376A1 (en) | 2018-01-17 |
| ES2824763T3 (es) | 2021-05-13 |
| AU2015254663A1 (en) | 2016-11-10 |
| CN106659738B (zh) | 2021-02-09 |
| PL3137093T3 (pl) | 2018-06-29 |
| CA2946928A1 (en) | 2015-11-05 |
| KR20160145822A (ko) | 2016-12-20 |
| ES2651537T3 (es) | 2018-01-29 |
| KR102388363B1 (ko) | 2022-04-19 |
| DK3137093T3 (en) | 2017-12-11 |
| AU2015254663B2 (en) | 2020-04-02 |
| CN106659738A (zh) | 2017-05-10 |
| SI3137093T1 (en) | 2018-01-31 |
| PT3137093T (pt) | 2017-12-19 |
| EP3137093B1 (en) | 2017-09-13 |
| HUE037501T2 (hu) | 2018-08-28 |
| EP3137093A1 (en) | 2017-03-08 |
| CY1119674T1 (el) | 2018-04-04 |
| JP2017518275A (ja) | 2017-07-06 |
| JP6692755B2 (ja) | 2020-05-13 |
| CA2946928C (en) | 2023-01-31 |
| LT3137093T (lt) | 2017-12-11 |
| WO2015165966A1 (en) | 2015-11-05 |
| EP3269376B1 (en) | 2020-07-15 |
| NO3137093T3 (enExample) | 2018-02-10 |
| US20170049812A1 (en) | 2017-02-23 |
| US10478454B2 (en) | 2019-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| MX2017007178A (es) | Formulaciones liquidas estables de virus de vacuna. | |
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| HRP20240231T1 (hr) | Farmaceutske formulacije inhibitora brutonove tirozin kinaze | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| HRP20180468T1 (hr) | Novi derivat analoga inzulina | |
| HRP20250899T1 (hr) | Manitol za uporabu u liječenju hepatotoksičnosti i masnih bolesti jetre | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| JP2018532806A5 (enExample) | ||
| WO2014160026A3 (en) | Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof | |
| WO2018025080A3 (en) | Compositions for enhancing brain activity | |
| IL281353A (en) | Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient | |
| WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
| BR112015005942A2 (pt) | extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica | |
| HRP20171896T1 (hr) | Liječenje i prevencija alzheimerove bolesti | |
| WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a | |
| HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| WO2012106058A3 (en) | Animal treatments | |
| JP2019529569A5 (enExample) | ||
| FI3137094T3 (fi) | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical |